Health and Fitness Health and Fitness
Tue, June 15, 2010
Mon, June 14, 2010

Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL to Support Greater Efficiencies in Clinical Development


Published on 2010-06-14 06:12:33 - Market Wire
  Print publication without navigation


PRINCETON, N.J.--([ BUSINESS WIRE ])--[ Bristol-Myers Squibb Company ] (NYSE: BMY) today announced that it has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the companya™s clinical development program.

"PAREXEL is proud to join this partnership, which is representative of leading models for outsourcing that have the potential to increase efficiency and create significant value."

Under the agreements, ICON and PAREXEL will provide global support for the execution of Bristol-Myers Squibba™s clinical studies to support its full development pipeline over the next three years. Because of a robust pipeline and significant inlicensing activity, Bristol-Myers Squibb is preparing for a large volume of clinical development work that will require expanding upon its existing partnering approach for clinical development. Consistent with the companya™s BioPharma strategy, the agreements with ICON and PAREXEL will complement the companya™s internal high-performing capabilities and capacity with high-quality clinical development services from partners who can drive efficiency and cost savings.

aThese partnerships will increase the operational capability of our clinical development organization, and support our industry-leading position in productivity and innovation,a said [ Brian Daniels ], senior vice president, Global Development, Bristol-Myers Squibb. aWorking with ICON and PAREXEL, two leaders in clinical research, Bristol-Myers Squibb will enhance support for our robust pipeline and improve our ability to deliver innovative medicines to patients with serious disease.a

aaWe are delighted that Bristol-Myers Squibb has selected us to support its global clinical development programs,a commented Dr. John Hubbard, ICON Group President Clinical Research Services. aOver the lasttenyears, we have forged a strong partnership by working hard to fully understand Bristol-Myers Squibba™s unique requirements.We look forward tomoving this partnership toanother levelandcontinuing tosupportBristol-Myers Squibba™s goal of bringinginnovative treatments to patients."

aWe look forward to a deeply collaborative relationship with Bristol-Myers Squibb to help provide innovative solutions for its growing pipeline, as well as leverage our global capabilities and worldwide technology infrastructure to support the effectiveness of its clinical development programs,a said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. aPAREXEL is proud to join this partnership, which is representative of leading models for outsourcing that have the potential to increase efficiency and create significant value.a

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit [ www.bms.com ] or follow us on Twitter at [ http://twitter.com/bmsnews ].

Contributing Sources